PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Megestrol Acetate

Drugs in development · updated 30 October 2026

Megestrol Acetate: clinical trials and development status

Other names and codes: Megace Es

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Megestrol Acetate is in 17 active clinical trials (recruiting or ongoing, phases I–III) for 14 diseases. The most advanced phase is III.

17Active trials
IIIMost advanced phase
14Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Megestrol Acetate and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Endometrial neoplasmIII6NCT07831902
Endometrial hyperplasiaII–III4NCT05316493
NeoplasmIII2NCT06500234
AnorexiaIII1NCT04939090
Breast neoplasmIII1NCT07543536
Hematologic neoplasmIII1NCT04939090
InfertilityII–III1NCT05316493
Nutrition disorderIII1NCT06500234
ObesityII–III1NCT05316493
OverweightII–III1NCT05316493
Uterine neoplasmIII1NCT07831902
Weight lossIII1NCT06998758
Adrenocortical carcinomaII1NCT05913427
Stomach neoplasmII1NCT07391826

Everything on Megestrol Acetate

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch